Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 13;34(2):ar9. doi: 10.1091/mbc.E22-06-0236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Collins et al. “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.

This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial-Share Alike 4.0 International Creative Commons License.

PMC Copyright notice

FIGURE 5: — Ras promotes mTORC2 activation in transformed MCF10A and breast cancer cells. AKT phosphorylation at the mTORC2-dependent site (S473; pAKT^S473) and total AKT proteins were detected by immunoblot as described in the Materials and Methods section. Immunoblots of pERK, ERK, HER2, and Ras were used as controls and performed as described in the Materials and Methods section. (A) pAKT^S473 levels in HER2/MCF10A and HRas^CA/MCF10A and cells compared with their respective MCF10A control cells. (B) MCF10A and HER2/MCF10A cells were pretreated with PTIs or 0.2% DMSO control. (C) MCF10A and HER2/MCF10A cells were pretreated with Pan-Ras siRNAs or nontargeting (NT) siRNA control. (D) The indicated breast cancer cells were treated with PTIs or 0.1% DMSO control. Graphs represent pAKT^S473 over total AKT levels quantified by densitometry and normalized to the control conditions ±SD of at least three independent experiments. *, p < 0.05.